Skip to main content
NewslettersWatchlist

Ardelyx Inc(ARDX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low4.82
Day High5.24
Open:4.94
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
GlobeNewswire
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
GlobeNewswire
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
GlobeNewswire
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
GlobeNewswire
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
GlobeNewswire
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
GlobeNewswire
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
GlobeNewswire
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
Barchart
3 Small-Cap Stocks Set To Skyrocket
The Globe and Mail
14 top U.S. equities to watch for price trend chasers
Motley Fool
Why Ardelyx Stock Soared Today
Motley Fool
Why Ardelyx Stock Popped Today
AllPennyStocks.com
Biotech Finds Mid-Week Success Following FDA Announcement
Motley Fool
Why Shares of Ardelyx Were Down Wednesday
Barchart
Markets Today: Stock Indexes Push Higher Ahead of Fed Chair Powell’s Speech
Barchart
S&P Futures Tick Higher Ahead of Powell’s Jackson Hole Speech
PR Newswire
Ardelyx, Inc. Reports Employment Inducement Grants
Barchart
Chart of the Day: Ardexlyx - Biotechnology
PR Newswire
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)

Profile

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.